Sergio Barrios

Sergio Barrios

Auto-generated profile, based on publicly available information

Sergio Barrios

David H. Koch Center for Applied Research of Genitourinary Cancers and Genitourinary Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
JGJason L. Guo
Jason L. Guo
YKYu Seon Kim
Yu Seon Kim
GKGerry L. Koons
Gerry L. Koons
JLJohnny Lam
Johnny Lam
ANAdam M. Navara
Adam M. Navara
AMAntonios G. Mikos
Antonios G. Mikos

16 June 2020 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
EMEric R. Molina
Eric R. Molina
LCLetitia K. Chim
Letitia K. Chim
SBSergio Barrios
Sergio Barrios
JLJoseph A. Ludwig
Joseph A. Ludwig
AMAntonios G. Mikos
Antonios G. Mikos
Investigations of cancer biology and screening of potential therapeutics for efficacy and safety begin in the preclinical laboratory setting. A staple of most basic research in cancer involves the use of tissue culture plates, on which immortalized cell lines are grown in monolayers. However, this practice has been in use for over six decades and does not account for vital elements of the tumor microenvironment that are thought to aid in initiation, propagation, and ultimately, metastasis of cancer. Furthermore, information gleaned from these techniques does not always translate to animal models or, more crucially, clinical trials in cancer patients. Osteosarcoma (OS) and Ewing sarcoma (ES) are the most common primary tumors of bone, but outcomes for patients with metastatic or recurrent disease have stagnated in recent decades. The unique elements of the bone tumor microenvironment have been shown to play critical roles in the pathogenesis of these tumors and thus should be incorporated in the preclinical models of these diseases. In recent years, the field of tissue engineering has leveraged techniques used in designing scaffolds for regenerative medicine to engineer preclinical tumor models that incorporate spatiotemporal control of physical and biological elements. We herein review the clinical aspects of OS and ES, critical elements present in the sarcoma microenvironment, and engineering approaches to model the bone tumor microenvironment. Impact statement: The current paradigm of cancer biology investigation and therapeutic testing relies heavily on monolayer, monoculture methods developed over half a century ago. However, these methods often lack essential hallmarks of the cancer microenvironment that contribute to tumor pathogenesis. Tissue engineers incorporate scaffolds, mechanical forces, cells, and bioactive signals into biological environments to drive cell phenotype. Investigators of bone sarcomas, aggressive tumors that often rob patients of decades of life, have begun to use tissue engineering techniques to devise in vitro models for these diseases. Their efforts highlight how critical elements of the cancer microenvironment directly affect tumor signaling and pathogenesis.

8 April 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
KZKejin Zhou
Kejin Zhou
LJLindsay T. Johnson
Lindsay T. Johnson
HXHu Xiong
Hu Xiong
SBSergio Barrios
Sergio Barrios
JMJonathan T. Minnig
Jonathan T. Minnig
DSDaniel Siegwart
Daniel Siegwart

20 February 2024 in Acta Biomaterialia
Verified
Journal Article
Closed access
CPClaudia Paindelli
Claudia Paindelli
VPVanessa Parietti
Vanessa Parietti
SBSergio Barrios
Sergio Barrios
PSPeter Shepherd
Peter Shepherd
TPTianhong Pan
Tianhong Pan
EDEleonora Dondossola
Eleonora Dondossola

18 September 2025 in Cancer Research
Verified
Journal Article
Closed access
LMLuca Marsilio
Luca Marsilio
SBSergio Barrios
Sergio Barrios
SMStefan Maksimovic
Stefan Maksimovic
AMAlice Maccarini
Alice Maccarini
ESElisa Serafini
Elisa Serafini
EDEleonora Dondossola
Eleonora Dondossola
Bone metastasis (BM) is a leading cause of morbidity and mortality in patients with prostate and renal cancer. The complex and dynamic biological processes driving its progression present significant challenges for both understanding and treating this disease. Although current in vivo research provides valuable insights, it is often limited by the inability to fully capture the intricate and multifactorial nature of BM. Thus, complementing existing in vivo models with multiscale computational approaches is crucial for dissecting the complex interactions between tumor cells and the bone microenvironment to advance our understanding of the metastatic process and therapy response. Accordingly, we developed a series of in vivo-inspired, spatially explicit, multicellular agent-based models of BM that effectively recapitulate key aspects of tumor progression, including angiogenesis and bone resorption. The digital twins were rigorously calibrated using in vivo data from prostate and kidney tumors. The models have utility for evaluating therapy response, as verified by the simulation of both the antiangiogenic effects of cabozantinib and the antiresorptive effects of zoledronic acid. These results highlight the predictive character of the agent-based models of BM in anticipating therapeutic outcomes and increasing our understanding of the complex dynamics of BM. Significance: The model offers a transformative tool for evaluating treatment strategies, including combination therapies, with the potential to accelerate the development of highly effective, targeted interventions for bone metastatic cancers. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel–Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC. However, limited data about their efficacy in BM is available, and no systematic comparisons have been performed. We developed mouse models of bone and lung ccRCC tumors and compared their anticancer efficacy, impact on mouse survival, and mechanisms of action, including effects on tumor cells and both immune and nonimmune (blood vessels and osteoclasts) bone stromal components. This approach elucidates the efficacy of TKIs in ccRCC bone tumors to support rational interrogation and development of therapies. Significance: TKIs showed different efficacy in synchronous bone and lung metastases and did not eradicate tumors as single agents but induced extensive reprogramming of the BM microenvironment. This resulted in a significant decrease in neoangiogenic blood vessels, bone remodeling, and immune cell infiltration (including CD8 T cells) with altered spatial distribution.